Richard E Kaufman Net Worth

The estimated Net Worth of Richard E Kaufman is at least $7.18 Milion dollars as of 10 July 2018. Richard Kaufman owns over 7,000 units of Intersect ENT Inc stock worth over $2,669,019 and over the last 10 years Richard sold XENT stock worth over $4,506,213.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Kaufman XENT stock SEC Form 4 insiders trading

Richard has made over 18 trades of the Intersect ENT Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Richard exercised 7,000 units of XENT stock worth $91,350 on 10 July 2018.

The largest trade Richard's ever made was selling 50,000 units of Intersect ENT Inc stock on 16 January 2018 worth over $1,666,500. On average, Richard trades about 7,016 units every 46 days since 2014. As of 10 July 2018 Richard still owns at least 94,512 units of Intersect ENT Inc stock.

You can see the complete history of Richard Kaufman stock trades at the bottom of the page.

What's Richard Kaufman's mailing address?

Richard's mailing address filed with the SEC is C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Intersect ENT Inc

Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt oraz W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.

What does Intersect ENT Inc do?

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.

Complete history of Richard Kaufman stock trades at Intersect ENT Inc

Intersect ENT Inc executives and stock owners

Intersect ENT Inc executives and other stock owners filed with the SEC include:

• Thomas West,
  President, Chief Executive Officer, Director
• Kieran Gallahue,
  Non-Executive Chairman of the Board
• Richard Meier,
  Chief Financial Officer, Executive Vice President
• Christine Kowalski,
  Chief Operating Officer, Executive Vice President
• Gwen Carscadden,
  Chief People Officer
• Thomas A. West,
  Pres, CEO & Director
• Richard A. Meier,
  Exec. VP & CFO
• Cynthia Lucchese,
  Independent Director
• Dana Mead,
  Independent Director
• William Vernon,
  Independent Director
• Teresa Kline,
  Independent Director
• Frederic Moll,
  Independent Director
• Patrick A. Broderick,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Reyna M. Fernandez,
  Chief Human Resource Officer
• Drake R. Parker,
  Advisor of Strategic Initiatives
• Jeryl L Hilleman,
  Chief Financial Officer
• Lisa D Earnhardt,
  
• Casey M Tansey,
  Director
• Amy Wolbeck,
  See Remarks
• Susan P Stimson,
  Vice President, Marketing
• Richard E Kaufman,
  See Remarks
• Drake R. Parker,
  Chief Business Officer
• David Aaron Lehman,
  EVP & General Counsel
• Neil A Hattangadi,
  
• Robert H Jr Binney,
  Chief Commercial Officer
• Rick D Anderson,
  Director
• Sciences Ii L P Pinto Techn...,
  
• Clercq Casper L. De,
  Director
• Sciences Ii L P Pinto Techn...,
  
• Perkins Caufield & Byers Xi...,
  
• James Stambaugh,
  VP, Clinical and Reimbursement
• Chas Mc Khann,
  Chief Commercial Officer
• Mark J Fletcher,
  Director
• Management Group Ix, L.L.C....,
  
• Venture Partners Xi, Lp Nor...,
  
• W Anthony Vernon,
  
• Reyna M Fernandez,
  Chief Human Resource Officer
• Patrick A Broderick,
  EVP, GC & Corporate Secretary
• Elisabeth Sandoval,